Internet Archive (Internet Archive)· 2020· Clinical trial

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

L.R. Baden

Short summary

The mRNA-1273 vaccine demonstrated 94.1% efficacy in preventing symptomatic COVID-19 after two doses in a large Phase 3 trial.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Infectious DiseasesMedicine